Mediolanum International Funds Ltd Sells 990 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Mediolanum International Funds Ltd trimmed its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 1.5% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 66,209 shares of the medical research company's stock after selling 990 shares during the period. Mediolanum International Funds Ltd's holdings in Thermo Fisher Scientific were worth $40,613,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Brookstone Capital Management lifted its stake in Thermo Fisher Scientific by 252.4% in the 1st quarter. Brookstone Capital Management now owns 4,387 shares of the medical research company's stock valued at $2,550,000 after acquiring an additional 3,142 shares in the last quarter. New England Research & Management Inc. acquired a new position in Thermo Fisher Scientific during the first quarter worth $349,000. KRS Capital Management LLC grew its position in Thermo Fisher Scientific by 6.2% in the first quarter. KRS Capital Management LLC now owns 1,430 shares of the medical research company's stock valued at $831,000 after purchasing an additional 83 shares in the last quarter. S.E.E.D. Planning Group LLC lifted its position in Thermo Fisher Scientific by 3.8% during the 1st quarter. S.E.E.D. Planning Group LLC now owns 10,178 shares of the medical research company's stock worth $5,916,000 after buying an additional 371 shares in the last quarter. Finally, Independence Bank of Kentucky boosted its stake in shares of Thermo Fisher Scientific by 4.3% during the 1st quarter. Independence Bank of Kentucky now owns 2,715 shares of the medical research company's stock worth $1,578,000 after buying an additional 112 shares during the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.

Thermo Fisher Scientific Price Performance

Shares of NYSE:TMO traded down $3.00 during trading on Friday, reaching $554.38. 1,086,281 shares of the company traded hands, compared to its average volume of 1,467,407. The company has a quick ratio of 1.37, a current ratio of 1.72 and a debt-to-equity ratio of 0.64. Thermo Fisher Scientific Inc. has a 52 week low of $420.21 and a 52 week high of $627.88. The firm has a market capitalization of $211.77 billion, a PE ratio of 34.72, a PEG ratio of 3.75 and a beta of 0.77. The company's 50 day moving average is $606.12 and its two-hundred day moving average is $584.21.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.25 by $0.03. Thermo Fisher Scientific had a net margin of 14.69% and a return on equity of 18.22%. The firm had revenue of $10.60 billion for the quarter, compared to the consensus estimate of $10.63 billion. During the same period in the prior year, the company posted $5.69 earnings per share. The business's revenue for the quarter was up .2% on a year-over-year basis. As a group, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 21.72 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on TMO shares. Bank of America increased their price target on Thermo Fisher Scientific from $600.00 to $675.00 and gave the company a "buy" rating in a research report on Monday, September 16th. Sanford C. Bernstein decreased their target price on shares of Thermo Fisher Scientific from $625.00 to $620.00 and set a "market perform" rating for the company in a research note on Thursday. Bernstein Bank upped their price target on shares of Thermo Fisher Scientific from $565.00 to $625.00 and gave the stock a "market perform" rating in a research report on Tuesday. Robert W. Baird lowered their price objective on shares of Thermo Fisher Scientific from $632.00 to $622.00 and set an "outperform" rating on the stock in a research note on Thursday. Finally, Barclays cut their target price on shares of Thermo Fisher Scientific from $620.00 to $610.00 and set an "equal weight" rating for the company in a research note on Wednesday. Five research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, Thermo Fisher Scientific has a consensus rating of "Moderate Buy" and an average target price of $649.33.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $617.21, for a total value of $6,172,100.00. Following the transaction, the chief executive officer now owns 123,816 shares in the company, valued at approximately $76,420,473.36. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 6,300 shares of the business's stock in a transaction on Monday, July 29th. The shares were sold at an average price of $602.09, for a total transaction of $3,793,167.00. Following the sale, the chief executive officer now owns 123,816 shares of the company's stock, valued at approximately $74,548,375.44. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $617.21, for a total value of $6,172,100.00. Following the completion of the transaction, the chief executive officer now owns 123,816 shares of the company's stock, valued at $76,420,473.36. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.34% of the company's stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.